Compare Dover Corp (DOV) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs Medpace Holdings Inc — how do they compare? Dover Corp trades at $208.23 (market cap $28.07B), while Medpace Holdings Inc trades at $600.79 (market cap $16.90B). The key difference: Dover Corp is the larger of the two by market cap, and Dover Corp pays a 1.01% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| DOV | MEDP | |
|---|---|---|
Market Cap | $28.07B | $16.90B |
Sector | Industrials | Technology |
52-Week High | $233.31 | $620.59 |
52-Week Low | $161.16 | $393.42 |
Enterprise Value | $29.58B | $16.52B |
Dividend Yield | 1.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOV trades at $207.92, down 1.04% on the day, with a bearish technical signal despite strong fundamentals. The company has beaten EPS estimates for three consecutive quarters, maintains a 13.48% net income margin, and recently raised its dividend. Analyst consensus is strongly bullish with a $232.33 price target. Recent news highlights manufacturing strength and strategic acquisitions like Cloeren, supporting growth in data center and AI segments.
The outlook is positive given earnings momentum, dividend growth, and raised 2026 guidance. Risks include market volatility and execution of acquisitions. With no sell ratings and solid cash flow, DOV offers a balanced opportunity for growth and income, though technical indicators suggest near-term caution.
MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.
Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
